--- title: 非酒精性脂肪肝病（NAFLD） description: NAFLD是一种容易诱发糖尿病以及其他威胁生命情况的严重疾病。Profil支持NAFLD的临床研究。 --- [![profil-logo-wortbild-with claim-4c-offset_1000px-1](https://www.profil.com/hs-fs/hubfs/profil-logo-wortbild-with%20claim-4c-offset_1000px-1.png?width=1000&name=profil-logo-wortbild-with%20claim-4c-offset_1000px-1.png "profil-logo-wortbild-with claim-4c-offset_1000px-1")](https://www.profil.com?hsLang=zh) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) # [![Header_1077x260px_Obesity_Treatment](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_Obesity_Treatment.jpg?width=1077&height=260&name=Header_1077x260px_Obesity_Treatment.jpg) MASLD / MASH 代謝功能障礙相關脂肪肝病（MASLD）](https://www.profil.com/zh/expertise/nafld#) ## MASLD, MASH与糖尿病 代謝功能障礙相關脂肪肝病（MASLD）是一种严重的疾病，它会诱发糖尿病和心血管疾病，以及肝硬化和肝细胞癌。根据Day和James在1998年提出的一个开创性概念，NAFLD的发展具有“二次打击”的特征。第一次打击是脂肪肝，表现为潜在的良性和可逆的肝细胞性甘油三酯沉积。如果发生第二次打击，则可能会向非酒精性脂肪性肝炎（NASH）发展：肝细胞与活性氧和炎性细胞因子的接触增加，导致肝细胞死亡和肝组织不可逆转的重塑。 局限于脂肪组织和肝脏的旁分泌信号回路，与胰岛素抵抗、发炎的脂肪组织和病变肝脏之间的相互作用，由脂肪衍生激素、炎症细胞和趋化因子、游离脂肪酸和肝脏因子（如FGF21、fetuin-A、IGF和IGFBPs、硒蛋白P、SHBG）的释放所介导的双向作用，已被认为是NAFLD的关键致病因素。在脂肪组织和肝脏中产生的炎症介质和促动脉粥样硬化介质会引发全身性状态，导致外周胰岛素抵抗、糖尿病和脉管系统中的动脉粥样硬化。显然，肝脏脂肪的量，而不是皮下腹部脂肪、内脏脂肪或细胞内脂质的量，描述了颈动脉内膜中层厚度 (IMT)正常的胰岛素敏感肥胖者与IMT明显增厚的胰岛素抵抗肥胖者之间的区别。正如在明显健康的人群中RISC（胰岛素敏感性和心血管疾病之间的关系）所证明的那样，脂肪肝的发生率与胰岛素抵抗（用高胰岛素正葡萄糖钳夹技术测定）、冠心病风险和早期动脉粥样硬化的征兆有关。 ### Profil的MASLD临床试验 Profil拥有各种相关手段可用于探索机理和早期阶段的临床试验，在高危的健康人群和糖尿病患者中解决与NAFLD相关的终点问题。 - 基于MRT和MRS的肝脏脂肪定量和肝脏能量代谢评估（与杜塞尔多夫德国糖尿病中心合作） - 通过两步高胰岛素正葡萄糖钳夹定量内源性葡萄糖抑制和肝胰岛素敏感性 - 通过间接测热法、呼气试验、甘油动力学和空气置换体积描记法等综合方法解决脂肪组织和肝脏之间的代谢沟通 - 通过间接测热法结合高度标准化的饮食疗法测量脂肪和葡萄糖的氧化程度 - 评估脂质分解（微透析、甘油动力学）和肝脏VLDL的分泌情况 - 以病原学概念为指导，对基于血液的生物标志物和替代物进行全面、有针对性的测定 - 进行血液采样以分析无血浆脂肪酸馏分中的脂肪酸特征 - IMT测量（高分辨率超声检查） - 用于确定脂肪肝和药物干预临床结果的遗传多态性分层（与杜伊斯堡-埃森大学药物遗传学研究所合作） - 进行脂肪和肌肉组织活检的准备，用于全面或专门定制的基因表达和组织病理学分析 - 准备用于线粒体和氧化代谢分析的肌肉组织活检 作为CBmed（医学生物标志物研究中心）的成员之一，Profil有能力将我们的综合服务组合与先进的 “组学”分析平台联系起来。我们可以使用欧洲最大的生物库（之一）、数字病理平台和生物信息学工具。   您有兴趣了解更多有关MASH和MASLD的内容？[点击此处观看我们有关该话题的网络研讨会。](https://info.profil.com/webinar-nash?hsLang=en-us) ** ** ![pikto2.png](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_NewWebinar.png?width=62&height=70&name=Icon_NewWebinar.png) ### 网络研讨会 网络研讨会点播: **"Diagnosis of MASLD ****– ** **Performance characteristics of available diagnostic procedures****"** [![立即观看](https://no-cache.hubspot.com/cta/default/481167/c30cefea-4735-47b1-8283-ff0d70fcc5f3.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/c30cefea-4735-47b1-8283-ff0d70fcc5f3) ![Leona_Hexagon_neu](https://www.profil.com/hs-fs/hubfs/Leona_Hexagon_neu.png?width=154&height=175&name=Leona_Hexagon_neu.png) ### 我们的专家 **Leona Plum-Mörschel 教授** 首席执行官 [![与她联系](https://no-cache.hubspot.com/cta/default/481167/f5565a87-4a31-4591-9868-dcb665c789be.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/f5565a87-4a31-4591-9868-dcb665c789be)   [![NAFLD_NASH_content](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/content-bilder/NAFLD/NAFLD_NASH_content.jpg?width=300&height=225&name=NAFLD_NASH_content.jpg) ![enlarge](https://www.profil.com/hubfs/BLUE_MOON/piktos/Lupe-01-1.svg) ](https://www.profil.com/hubfs/BLUE_MOON/content-bilder/NAFLD/NAFLD_NASH.jpg/medium.jpg?t=1441636919351&hsLang=zh) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://www.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://www.profil.com/knowledge-center/references?hsLang=zh) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Poll LW. et al., 2004. A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. Diabetes Technol Ther 2004; 6:844-849. [View all](https://www.profil.com/knowledge-center/publications?hsLang=zh) Non-alcoholic fatty liver disease (NAFLD) is an emergent disease that predisposes for diabetes, cardiovascular disease, liver cirrhosis and hepatocellular carcinoma. Profil has the expertise to support clinical investigations of NAFLD with methods including; MRT- and MRS-based quantification of liver fat and assessment of the hepatic energy metabolism; quantification of endogenous glucose suppression and hepatic insulin sensitivity by means of a two-step hyperinsulinemic euglycemic clamp; addressing the metabolic communication between adipose tissue and the liver with an integrated methodological approach combining indirect calorimetry, breath tests, glycerol kinetics and air displacement plethysmography; measurement of fat and glucose oxidation via indirect calorimetry combined with a highly standardized dietary regimen; assessment of lipolysis (microdialysis, glycerol kinetics) and hepatic VLDL secretion; comprehensive and specifically tailored blood-based assaying of biomarkers and surrogates guided by a pathogenetic concept; blood sampling for the profiling of fatty acid signatures in the plasma-free fatty acid fraction; IMT measurement; preparation of adipose and muscle tissue biopsies for comprehensive or specifically tailored gene expression and histopathological analyses; and preparation of muscle tissue biopsies for analyses of mitochondria and oxidative metabolism. ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=zh) | [Privacy Policy](https://www.profil.com/privacy?hsLang=zh)